Phrixus Pharmaceuticals is developing Carmeseal™ (poloxamer 188 or P188) for
Duchenne muscular dystrophy and acute decompensated heart failure.


Phrixus Pharmaceuticals receives services from National Institutes of Health, NHLBI SMARTT Program to produce Carmeseal-­MD™ for clinical trial to treat Duchenne muscular dystrophy

read more


Phrixus has concurrence with FDA on the following:

1600 Huron Parkway, Building 520, 2nd Floor, Ann Arbor, MI 48109 (734) 358-9015
thomas.collet (at)
Created by J&M Marketing Communications /